Trial
NCT03957876
CPX-351 Therapy for MDS After Hypomethylating Agent Failure
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Case Comprehensive Cancer Center
Collaborators
—
Condition
Myelodysplastic Syndrome (MDS)
Intervention
CPX-351
Why stopped
Slow Accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-08-15